1 rich Libsyn https://www.libsyn.com 90 600 What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on&amp;nbsp;her article, “Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.”&amp;nbsp;They examine differences in pCR by estrogen receptor status and the clinicopathologic and HER2DX features associated with response, while considering how these findings may inform treatment personalization as the trial’s 3-year recurrence-free survival data mature. LINK TO FULL TRANSCRIPT Journal of Clinical Oncology (JCO) Podcast http://sites.libsyn.com/58526 <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/42592410/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/00457c/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/42592410